Denmark's Novo Nordisk has seen its shares surge on the news that Liraglutide has produced positive results in two late-stage trials, positioning it for regulatory approval next year. The two Phase III trials are the second and third legs among five late-stage studies of the drug. And in these two steps the drug reduced weight and improved glucose control. Roughly 40 percent of patients hit the American Diabetes Association's goal of average blood glucose control (HbA1c) of 7 percent.
"The encouraging clinical results from the two new trials confirm the positive effect of Liraglutide...and leave us confident that we are on track to submit for regulatory approval mid-2008," said Novo Nordisk chief science officer Mads Krogsgaard Thomsen.
- check out the release
- read the report from the PharmaTimes